Marrow Therapeutics Launches With $173M Series A and B for Bone Marrow-Targeted Genetic Medicines


Marrow Therapeutics, a U.S. biotech startup built around antibodies that carry drugs only to bone marrow, has launched with $173 million in combined funding, a $53 million Series A and a $120 million Series B. It wants to treat sickle cell disease and beta thalassemia with a single injection.

Marrow Therapeutics logo

Marrow Therapeutics is a genetic medicines company based in Watertown, Massachusetts. According to press reports, Scion Life Sciences formed and incubated it in 2024, and it spent nearly three years developing its technology quietly. It builds a drug delivery system that sends genetic medicines to a chosen place in the body and uses it to develop its own drugs, rather than only licensing the technology to others.

Sickle cell disease and beta thalassemia are inherited disorders of hemoglobin, the protein in red blood cells that carries oxygen. In sickle cell disease, red cells bend into a sickle shape and block blood vessels; in beta thalassemia, the body cannot make enough healthy red cells. Patients live with lifelong anemia, pain and organ damage. Gene-editing therapies are already approved, but they are burdensome: a patient’s bone marrow stem cells are removed, their DNA is edited outside the body, and the cells are infused back after harsh chemotherapy that clears the marrow, at a list price of $2.2 million to $3.1 million (press reports).

Marrow goes after the same diseases differently. Before birth, babies carry oxygen with fetal hemoglobin, and after birth a gene called BCL11A switches it off. Turning that switch back down revives fetal hemoglobin and eases symptoms. Casgevy, the approved therapy, targets the same switch but edits cells outside the body. Marrow wants to turn it down with an injection that reaches the marrow directly, without removing any cells.

The platform is called TAB, short for Transferrin Antibody Bioconjugate. The antibody, a protein that sticks only to a specific target, is the delivery truck. Its destination is the transferrin receptor (TfR1), the door cells use to take in iron, which is especially abundant on the bone marrow cells that make blood. The cargo is siRNA, a small RNA molecule that stops a specific gene from being turned into protein. It does not change DNA; it removes the working copy of the gene’s instructions and turns its output down.

The first candidate, MAR-101, is the first drug built on the TAB platform: an antibody conjugated to an siRNA. It targets both diseases. According to press reports, the antibody carries an siRNA against BCL11A to bring back fetal hemoglobin production. It is in IND-enabling studies, the preclinical work needed before regulators allow tests in people, and press reports say the aim is a subcutaneous self-injection that is stable at room temperature. The company says monkey studies showed bone marrow target engagement, BCL11A knockdown and fetal hemoglobin induction, and that results in human cells are on par with or better than ex vivo editing approaches. It has not released the data, and MAR-101 has not been tested in people.

Using a receptor like TfR1 as the destination for drug delivery has been validated elsewhere. According to press reports, a drug from Denali that binds TfR was approved for Hunter syndrome in March, and Dyne Therapeutics and Avidity Biosciences use the same receptor for muscle diseases.

Questions remain, though. One outlet noted that Marrow raised its money without releasing anemia or selectivity data. Because TfR1 is how cells take in iron, an antibody that interferes with it could starve developing red blood cells of iron and cause anemia. The company says its experience with TfR1 lets it avoid that risk. TfR1 is also present on many cell types, and BCL11A is needed for B-cell development, so the question is whether the drug can be confined to the red-cell lineage. Because siRNA does not change DNA, how long the effect lasts and how often patients would need injections are also open. The company has not disclosed its antibody sequences or patent position.

Romesh Subramanian is President and CEO. According to press reports he was CEO and chief scientific officer of Dyne Therapeutics and later led Ascidian Therapeutics. Tim Weeden, chief scientific officer, has experience in transferrin receptor biology and antibody and nucleic acid development, and John Najim, chief operating officer and chief technology officer, leads chemistry, manufacturing and controls (CMC). Press reports say both also come from Dyne. Gavriel Mullokandov is founder and VP of corporate development. Art Levin, founding chief scientific officer of Avidity Biosciences, joined the board, and Stuart Orkin of Harvard Medical School joined the scientific advisory board.

Marrow announced the funding. Scion Life Sciences and venBio co-led the Series A, which press reports say was raised in early 2025 but not announced while Marrow shored up its intellectual property. OrbiMed led the Series B, with all Series A investors plus RTW Investments, Surveyor Capital (a Citadel company), Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital and Columbia Threadneedle Investments. The company did not disclose a valuation.

According to press reports the money goes toward readying the clinic and building manufacturing capacity. It did not give a clinical start date, and Scion said it expects the programs to enter the clinic in the coming year.

Its competitors are the gene-editing therapies already on the market. According to press reports, Vertex‘s Casgevy, which uses CRISPR to lower BCL11A expression, is approved at a $2.2 million list price, and Genetix‘s Lyfgenia is priced at $3.1 million. Both require chemotherapy conditioning to clear the marrow. Efforts to edit stem cells inside the body continue as well: Tessera reported in May that it achieved average long-term blood stem cell editing of 85% in non-human primates, according to press reports.

Marrow lowers expression of the same target with siRNA instead of editing, and it is betting on delivery. The flow of capital into delivery-focused gene therapy startups also shows in Estuary’s $103 million launch for kidney delivery and Epicrispr’s $90 million Series C for epigenetic editing. But Marrow’s drug has not been given to people, and until safety and selectivity data appear, the case rests on the company’s account.

Share

Leave a Reply

Your email address will not be published. Required fields are marked *